Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process

Cancer Research

Volumn 67, Issue 10, 2007, Pages 5009-5016

  Preynat Seauve, Olivier ^a   Contassot, Emmanuel ^a   Schuler, Prisca ^a   Piguet, Vincent ^b   French, Lars E ^a   Huard, Bertrand ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CLONAL ANERGY; CONTROLLED STUDY; CROSS PRESENTATION; CROSS TOLERANCE; HELPER CELL; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHOID ORGAN; MELANOMA B16; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; IMMUNE TOLERANCE; LYMPH NODES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS;

EID: 34250356289     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4494     Document Type: Article

References (31)

1. Sporn MB. The war on cancer. Lancet 1996;347:1377-81.
2. Santin AD. Lymph node metastases: the importance of the microenvironment. Cancer 2000;88:175-9.
3. Kundig TM, Bachmann MF, DiPaolo C, et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995;268:1343-7.
4. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.
5. Bubenik J. Tumour MHC class I downregulation and immunotherapy (review). Oncol Rep 2003;10:2005-8.
6. Ramaswamy S, Ross KN, Lander KS, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
7. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 2005;102:6092-7.
8. Holler N, Tardivel A, Kovacsovics-Bankowski M, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 2003;23:1428-40.
9. Kalergis AM, Goyarts EC, Palmieri K, et al. A simplified procedure for the preparation of MHC/peptide tetramers: chemical biotinylation of an unpaired cysteine engineered at the C-terminus of MHC-T. J Immunol Methods 2000;234:61-70.
10. 2 terminus. J Biol Chem 1982;257:12245-51.
11. Arrighi JF, Pion M, Wiznerowicz M, et al. Lentivirus-mediated RNA interference of DC-SIGN expression inhibits human immunodeficiency virus transmission from dendritic cells to T cells. J Virol 2004;78:10848-55.
12. Huard B, Arlettaz L, Ambrose C, et al. BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol 2004;16:467-75.
13. Maloy KJ, Erdmann I, Basch V, et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci U S A 2001;98:3299-303.
14. Preynat-Seauve O, Schuler P, Contassot E, et al. Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J Immunol 2006;176:61-7.
15. Wells AD, Gudmundsdottir H, Turka LA. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Invest 1997;100:3173-83.
16. Ochsenbein AF, Klenerman P, Karrer U, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999;96:2233-8.
17. + T cells. J Exp Med 2003;198:569-80.
18. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
19. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-64.
20. Kumar V, George T, Yu YY, et al. Role of murine NK cells and their receptors in hybrid resistance. Curr Opin Immunol 1997;9:52-6.
21. van Mierlo GJ, den Boer AT, Medema JP, et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A 2002;99:5561-6.
22. Nguyen LT, Elford AR, Murakami K, et al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med 2002;195:423-35.
23. + T cells pass through an effector phase during the process of in vivo tolerance induction. J Immunol 2003;170:3945-53.
24. Ohlen C, Kalos M, Cheng LE, et al. CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J Exp Med 2002;195:1407-18.
25. Vezys V, Olson S, Lefrancois L. Expression of intestine-specific antigen reveals novel pathways of CD8 T cell tolerance induction. Immunity 2000;12:505-14.
26. Shen L, Rock KL. Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci U S A 2004;101:3035-40.
27. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000;192:1685-96.
28. Belz GT, Behrens GM, Smith CM, et al. The CD8α(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002;196:1099-104.
29. Dudziak D, Kamphorst AO, Heidkamp GF, et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007;315:107-11.
30. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med 1997;186:2057-62.
31. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.